Cholesterol-Lowering Therapy Interventions
- 4 Downloads
Elevated cholesterol levels are associated with an increased risk of cardiovascular diseases. Treatment strategies promoting the associated health benefits from a reduction in elevated cholesterol levels have been outlined in guidelines published by the National Cholesterol Education Program. Clinicians and researchers have also examined the economic benefits associated with reducing elevated cholesterol levels. Most of these studies have employed traditional pharmacoeconomic techniques like cost-effectiveness analysis. Results from these studies indicated that certain types of therapy interventions (such as the use of cholesterol-lowering pharmaceutical agents) are cost effective. However, the majority of these studies are clinically driven and rely heavily on cost-outcome ratios as decision variables.
This traditional approach to pharmacoeconomic evaluation is starting to be questioned by managed care organisations in the US. These organisations are increasingly interested in assessing the global (or health systems-based) impact associated with the introduction of a therapy intervention (such as cholesterol lowering agents). Subsequently, there is a need for pharmacoeconomic studies to provide a health systems-based view to assess a range of competing cholesterol-lowering treatment options.
KeywordsAdis International Limited Simvastatin Lovastatin National Cholesterol Education Program Manage Care Organisation
Unable to display preview. Download preview PDF.
- 1.National Cholesterol Education Program second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute; 1993. NIH publication no. 93–3095Google Scholar
- 2.Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993; 269: 3015–23CrossRefGoogle Scholar
- 7.Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69Google Scholar
- 8.American College of Physicians. Guidelines for using serum cholesterol, high density lipoprotein, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996; 124: 515–7Google Scholar
- 13.Langley PC, Sullivan SD. Pharmacoeconomic evaluations: guidelines for drug purchasers. J Managed Care Pharm 1996; 2: 671–7Google Scholar
- 14.Phelps ES. Equilibrium: an expectational concept. In: Eatwell J, Milgate M, Newman P, editors. The New Palgrave: a dictionary of economics. Vol. 2. New York: Stockton Press, 1987: 177–9Google Scholar
- 15.Folland S, GoodmanZ AC, Stano M. The economics of health and health care. 2nd ed. New Jersey: Prentice Hall, 1997Google Scholar
- 23.Hilleman DE, Pincus KT, Wadibia EC, et al. Comparative cost-effectiveness of bile acid sequestering resins, HMG Co-A reductase inhibitors, and their combination in patients with hypercholesterolemia. J Managed Care Pharm 1995; 1: 188–92Google Scholar
- 37.Armstrong EP, Manuchehri F. Ambulatory care databases for managed care organizations. Am J Health Sys Pharm 1997; 54: 1973–83Google Scholar
- 38.Else BA, Armstrong EP, Cox ER. Data sources for pharmacoeconomic and health service research. Am J Health Sys Pharm 1997; 54: 2601–8Google Scholar